The Hypertriglyceridemia Therapeutics Market Is Growing with Increasing Prevalence of Cardiovascular Diseases

Hypertriglyceridemia Therapeutics Market


 Hypertriglyceridemia is an augmented level of triglycerides, a type of lipid, in the bloodstream, which are mainly related to cardiovascular diseases (CVDs), atherosclerosis, and other CVDs. The hypertriglyceridemia therapeutics market is gaining huge traction due to the advancements in terms of diagnosis and treatment of hypertriglyceridemia to rapidly recover triglyceride levels in the body. For instance, in December 2019, HLS Therapeutics announced that Health Canada has approved the use of Vascepa to reduce the risk of cardiovascular events in patients with elevated triglycerides and those who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetes, or at least one cardiovascular risk factor.

Treatment of hypertriglyceridemia comprises diuretics, beta-blockers, estrogen therapy, and corticosteroids. The hypertriglyceridemia therapeutics market is expected to witness robust growth in North America, owing to increasing product launches and approvals in the region. For instance, in March 2021, Arrowhead Pharmaceuticals submitted an Investigational New Drug Application to the Food and Drug Administration (FDA) for ARO-APOC3, a drug candidate developed for the treatment of hypertriglyceridemia. Moreover, in January 2020, Akcea Therapeutics and Ionis Pharmaceuticals announced the results of phase 2 trial featuring AKCEA-ANGPTL3- LRx, a drug candidate developed to combat hypertriglyceridemia.

Growth of the hypertriglyceridemia therapeutics market is mainly driven by the increasing sedentary habits and the increasing prevalence of cardiovascular diseases. According to the World Health Organization (WHO), worldwide, cardiovascular diseases (CVDs) are the leading cause of death, taking an estimated 17.9 million lives each year. Moreover, the hypertriglyceridemia therapeutics market has witnessed tremendous growth due to the emergence of COVID-19. According to the EMCrit Project, people with COVID-19 are more prone to developing hypertriglyceridemia, mainly due to systemic inflammation. Thus, market players are focused on developing safe and effective hypertriglyceridemia therapeutics.

The ongoing research and development for the development of novel drugs for the treatment of hypertriglyceridemia is also responsible for the hypertriglyceridemia therapeutics market growth. For instance, in 2019, Arrowhead Pharmaceuticals initiated a phase I study of ‘ARO-APOC3’ for the treatment of hypertriglyceridemia. However, the high cost of treatment and medical care in emerging economies is restraining the market growth. Furthermore, the increasing prevalence of obesity is also responsible for the hypertriglyceridemia therapeutics market growth. According to the Trust for America's Health, a non-profit organization, in 2020, the U.S. adult obesity rate stands at 42.4%, the national adult obesity rate has increased by 26% since 2008.

Comments

Post a Comment

Popular posts from this blog

Astrum Has Expanded Its Presence In India Infrared Thermometer Market

Image
  The Infrared Thermometer market is witnessing the fastest growth in the Asia Pacific region and this can be accredited to the growing aging population in the region which is driving demand for healthcare services. Japan has the highest growing aging population in the country. According to the Statistics Bureau, Ministry of Internal Affairs and Communications, in 2019, the aged population (65 years old and over) was 35.89 million, constituting 28.4 percent of the total population (i.e., 1 in every 4 persons) and marking a record high in Japan. The rise in prevalence of infectious disease and increase in the demand for the product for newborns as children cannot hold the contact thermometer is playing a key role in the overall development of the infrared thermometer market . According to the World Health Organization, HIV, tuberculosis, malaria, neglected tropical diseases, and viral hepatitis affects billions of people around the world and causes more than 4 million deaths each year
Read more

The Global Meningococcal Vaccines Market Continues To Grow Owing To the Demand from Healthcare Care Sectors across the World to Prevent the Spread of the Diseases Especially In Children

Image
  Meningococcal vaccines prevent the contraction of meningococcal diseases, including meningitis caused by the bacteria called meningococcus aureus. An outbreak of meningococcal disease is usually followed by an onset of meningitis. Meningococcal meningitis can cause permanent damage to the brain or spinal cord in as little as 10 days, depending on the degree of infection and the natural immunity of the person. Since meningitis is usually associated with a fever and signs and symptoms of a serious illness, many parents prefer not to use the traditional treatments for their children such as meningitis or oral antibiotics. Instead, they often resort to various forms of therapeutic interventions that may even improve their chances of developing a positive outcome. Meningococcal vaccines are now available for meningococcal meningitis, as well as for men who have had other prior bouts of meningitis. Some vaccines used for these purposes are PPSV, Rallo, and Q fever type 1. These vaccines
Read more

Increasing Geriatric Population Is Driving the Growth of the Sexual Health Market

Image
       Sexual health is an important part of a person’s physical and mental health. According to the World Health Organization (WHO), sexual health requires a respectful and positive approach to sexual relationships and sexuality, as well as the possibility of having pleasurable and safe sexual experiences, free of coercion, violence, and discrimination. Sexual health leads to a healthy sex life without any sexually transmitted diseases, and to take preventive measures to avoid sexually transmitted infections. The elderly population (geriatric population) often suffer from one or more sexual disorders, such as premature (early) ejaculation, erectile dysfunctions, dyspareunia, and hypoactive sexual desire disorder, among others. Thus, with the increasing geriatric population worldwide, the prevalence/incidence of sexual disorders is also increasing, driving the growth of the sexual health market . According to WHO, the world's population aged 60 years and older is expected to tota
Read more